Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting

Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting

TOKYO, Japan, 23 May 2025: — PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the analysis of a combination study of E7386, created through collaboration research with Eisai Co., Ltd. , and Lenvatinib mesylate (“lenvatinib”) will be presented by...

Announcement: Investor Relations Seminar for Individual Investors

CEO Dai Takehara will participate in the “103rd IR Seminar for Individual Investors” hosted by Logmi Finance on Saturday, May 17, 2025. As a company committed to sustainable growth and corporate value enhancement, we actively promote dialogue with shareholders and investors through our proactive IR activities. We will continue our efforts to communicate information and...

Featured in Nikkei Biotech

Nikkei Biotech has published an interview with our CEO Dai Takehara, and our Director/Head of R&D Dr. Park. Special Feature: Peptide Drug Discovery Finally Taking Off “The Future of PPI Drug Discovery: A Conversation with PRISM BioLab CEO Dai Takehara” https://bio.nikkeibp.co.jp/atcl/news/p1/25/04/15/13203/

Featured in The Nikkei

PRISM BioLab has been featured in The Nikkei (Nihon Keizai Shimbun). “PRISM BioLab and AI Drug Discovery Startup Partner for Efficient Drug Development” https://www.nikkei.com/article/DGXZQOUC1173U0R10C25A4000000/

PRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug Discovery for Protein-Protein Interaction Targets

TOKYO, Japan, 14 April 2025 — PRISM BioLab, Co. Ltd., a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a drug discovery collaboration with Elix, Inc., effective April 1, 2025. This partnership will accelerate research on these challenging molecular targets by...

Announcement: Participation in LINK-J’s Miyaman’s Venture Talk vol.12

We are pleased to announce that our CEO, Takehara, will be speaking at Miyaman’s Venture Talk vol.12, hosted by the Life Science Innovation Network Japan (LINK-J). In this event, he will join Mr. Miyata to discuss the latest advancements in the development of protein-protein interaction inhibitors. Event Details: Date & Time: Friday, March 7, 2025,...

Announcement of Appointment and Resignation of Directors

We are pleased to announce that at our Ordinary General Meeting of Shareholders held on December 26, 2024, the following director was appointed and assumed office as of the same date: Director : Shinji Takeuchi (General Manager, Administration Department) Additionally, Director Tomohiro Maeda resigned from his position effective December 26, 2024.

Our CEO Takahara Featured on “IRTV” Video Media

Our CEO, Takahara, recently appeared on IRTV, a video platform connecting investors and companies. YouTube: IRTV – “July 2, 2024 IPO! Discover the Secrets of PepMetics® Technology: A New Era in Drug Discovery” https://youtu.be/7_xlnd5ECQ4

Scroll to top
en_USEnglish